Primary Question: Is there a reduction in the levels of inflammatory cytokines, oxidative stress biomarkers, pain levels, and physical function in osteoarthritis patients after curcumin supplementation compared to the control group? Secondary Question: Is there a reduction in the levels of inflammatory cytokines, oxidative stress biomarkers, pain levels, and physical function in osteoarthritis patients after curcumin supplementation compared to the same patients before curcumin supplementation?
Conditions
Interventions
Meriva Curcumin Phytosome 250 mg (providing 50 mg Curcuminoids) from Mega Lifesciences Public Company Limited,
The experimental group received Curcumin extract (CURCARE PHYTO) 500 mg per day (250 mg/
Experimental Dietary Supplement,Placebo Comparator No treatment
Curcumin,Control
Sponsors
None listed
Eligibility
Sex/Gender
All
Age
50 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Patients with primary osteoarthritis of the knee. 2.Patients aged 50-80 years. 3.Patients diagnosed with osteoarthritis according to 4.ACR criteria and having knee X-ray results with Kellgren-Lawrence (KL) grade 1-3. 5.Patients with a VAS pain score of 5 or higher. 6.Patients who have not undergone total knee replacement surgery previously. 7.Patients who have not received NSAIDs within the last 3 months. 8.Patients who have not received intra-articular steroid injections or lubricants within the last 3 months. 9.Individuals capable of providing informed consent independently. 10.Individuals who do not have lactose intolerance.
Exclusion criteria
Exclusion criteria: 1.Patients with other types of arthritis, such as rheumatoid arthritis, SLE, gout, etc., including patients with psoriasis, those with a history of knee injury, those with a history of joint infection, and cancer patients Patients with impaired immune system function, such as those receiving immunosuppressive drugs, those with congenital immunodeficiency diseases, and those infected with human immunodeficiency viruses (HIV). 2.Patients with abnormal liver and kidney function. 3.Patients with an allergy to curcumin. 4.Patients with an allergy to NSAIDs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Inflammatory marker (IL-1b and IL-6) Day 0 and 30 enzyme-linked immunosorbent assay,Oxidative stress Day 0 and 30 8-OHdG enzyme-linked immunosorbent assay,miRNA expression Day 0 and 30 Real time Polymerase Chain Reaction | — |
Secondary
| Measure | Time frame |
|---|---|
| physical function Day 0 and 30 physical performance | — |
Countries
Thailand
Contacts
Public ContactSittisak Honsawek
Chulalongkorn University
Outcome results
None listed